1. Generics Bulletin
  2. >>Business
  3. >>Deals

Sandoz Bolsters Respiratory Aspirations With Coalesce Acquisition

Addition Of UK-Based Drug Delivery Device Firm Adds To Complex Capabilities

 
• By Dave Wallace

Sandoz is targeting growth opportunities in the respiratory complex generics space with the acquisition of UK-based drug delivery device firm Coalesce.

Woman With Inahler, Breathing In
Sandoz has acquired a respiratory device specialist • Source: Antonio Guillem Fernández / Alamy Stock Photo

Sandoz has revealed its latest move to capture growth opportunities in respiratory and complex generics with the announcement that it has acquired UK-based drug delivery device development company Coalesce Product Development Limited.

While financial details of the transaction and specific product opportunities were not revealed by the Novartis subsidiary – which is still the subject of a strategic review by its parent company (see sidebar), with more details expected to be disclosed later this year – Sandoz said the acquisition would build

More from Deals

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.